Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

Canadian Cancer Trials Group MA.17R -- A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study)-- was closed to accrual on 8 May 2009.